CA - Aeterna stock rises ~10% after Pharmanovia acquires rights to Ghryvelin in EU UK

2023-03-16 08:39:43 ET

• Aeterna Zentaris ( NASDAQ: AEZS ) said Pharmanovia acquired licensing rights to growth hormone therapy Ghryvelin from Aeterna's existing licensee Consilient Health.
• Pharmanovia acquired exclusive rights and license to commercialize Ghryvelin (macimorelin) in the European Economic Area (EEA) and the U.K. for treating Growth Hormone Deficiency (AGHD) and, if approved, for Childhood Onset Growth Hormone Deficiency (CGHD).
• "Pharmanovia has established global expertise in marketing diagnostic testing solutions in addition to an established footprint in endocrinology across Europe. They are positioned as the natural choice as our commercialization partner moving forward," said Aeterna CEO Klaus Paulini.
• Macimorelin is marketed as Ghryvelin in the U.K. and EEA and as Macrilen in the U.S.
• Aeterna noted that in 2022 the company said that it will regain full rights to Macrilen from Novo Nordisk ( NVO ) for the U.S. and Canada in May 2023. The company added that it is seeking an alternate partner for Macrilen in the U.S., Canada and other territories currently not partnered.
• AEZS +11.24% to $2.97 premarket March 16

For further details see: